CLASS II Drug recall · Reported 21 Feb 2024 · FDA Enforcement Report

HydrALAZINE Hydrochloride Tablets, USP 10mg recalled

The Harvard Drug Group is recalling HydrALAZINE Hydrochloride Tablets, USP 10mg, distributed nationwide in the US. The recall was initiated on 9 Feb 2024 and the FDA has classified it as Class II.

Check your package

Lot, batch or date codesLot #: T04680, Exp. Date 6/2024
Quantity recalled8,198 units

Check the lot number on your package against the affected lots. If it matches, contact the pharmacy that dispensed it or your prescriber before stopping any medication.

Recall details

Recall number
D-0324-2024
FDA event ID
93929
Recalling firm
The Harvard Drug Group, La Vergne, TN
Classification
Class II
Status
Terminated
Recall initiated
9 Feb 2024
FDA classified
13 Feb 2024
Reported
21 Feb 2024
Type
Voluntary: Firm initiated
Customers notified by
E-Mail
Reason category
Potency & Assay

Timeline

9 Feb 2024Recall initiated by company
13 Feb 2024Classified by FDA+4 days
21 Feb 2024Published in enforcement report+8 days

Companies usually start a recall weeks before the FDA classifies and publishes it; the gap above is that lag.

Reason for recall

an out of specification result obtained during routine stability testing for Impurities. There is a remote possibility that use of this product could cause a medically reversible or transient adverse health consequences.

Potency and specification recalls happen when a batch tests outside its approved limits for strength, purity or dissolution, which can mean the dose delivered is higher or lower than labelled.

Product as listed by the FDA

HydrALAZINE Hydrochloride Tablets, USP 10mg, packaged in 100-count (10x10 blister cards), Lot T04680, Rx only, Manufactured for Heritage Pharmaceuticals, Inc. Eatontown, NJ, Distributed by Major Pharmaceuticals Livonia MI. NDC 0904-6440-61

Where it was distributed

The product was distributed nationwide within the United States.

Nationwide

Questions about this recall

Why was it recalled?

an out of specification result obtained during routine stability testing for Impurities. There is a remote possibility that use of this product could cause a medically reversible or transient adverse health consequences.

Which lots are affected?

Lot #: T04680, Exp. Date 6/2024

Where was it sold?

The product was distributed nationwide within the United States.

What should I do if I have it?

Check the lot number on your package against the affected lots. If it matches, contact the pharmacy that dispensed it or your prescriber before stopping any medication.

What does Class II mean?

Class II means the product may cause temporary or medically reversible health problems, or the probability of serious harm is remote.

Read the official FDA notice · Source record retrieved 26 Sep 2026. The FDA describes openFDA data as unvalidated; the official notice takes precedence. This page reports the record and gives no medical advice.

More recalls from The Harvard Drug Group

All 79

Other Hydralazine recalls

All 17